Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer.

Clin Transl Oncol · 2014 · PMC4194027 · PMID 25223744

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients treated with regorafenib showed a trend towards benefit in all clinical subgroups in the CORRECT trial, including patients presenting KRAS mutation.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.